3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Cyclophosphamide
2
umbralisib
1
ublituximab
1
prednylidene
1
fludarabine phosphate
1
epratuzumab
1
deltacortene
1
cc-486
1
Whole-Body Irradiation
1
Vincristine
1
Thiotepa
1
Specimen Handling
1
Rituximab
1
Radioimmunodetection
1
Prednisone
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Hyaluronoglucosaminidase
1
Etoposide
1
Doxorubicin
1
Carboplatin
1
CT-P10
1
Busulfan
1
Bendamustine Hydrochloride
1
Azacitidine
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma, B-Cell, Marginal Zone
×
umbralisib
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA